SH-BC-893 |
| Catalog No.GC70569 |
SH-BC-893 is an orally active anti-neoplastic sphingolipid analog.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1841409-92-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SH-BC-893 starves cancer cells to death by down-regulating cell surface nutrient transporters and blocking lysosomal trafficking events[1].
SH-BC-893 (5 μM; 3 h) protects from ceramide-induced mitochondrial network fragmentation by disrupting intracellular trafficking[2].
SH-BC-893 (8.935 nM; 3 h) protects from ceramide-induced mitochondrial dysfunction[2].
SH-BC-893 (oral; 120 mg/kg; single) robustly and acutely blocks ceramide-induced mitochondrial dysfunction, correcting diet-induced obesity and its metabolic sequelae[1].
References:
[1]. Kubiniok, Peter et al. Dynamic Phosphoproteomics Uncovers Signaling Pathways Modulated by Anti-oncogenic Sphingolipid Analogs. Molecular & cellular proteomics : MCP vol. 18,3 (2019): 408-422.
[2]. Jayashankar, Vaishali et al. Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity. EMBO molecular medicine vol. 13,8 (2021): e13086.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *